Skinvisible, Inc. (SKVI) stock
SKVIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.16+0.00 (+0.06%)
Close on Oct 19, 2026Market cap $843.54KP/E –Yield –
Skinvisible gross margin
Gross margin is gross profit as a percentage of revenue.
Skinvisible's gross margin for the twelve months ending Jun 30, 2026 was 100.0%. For fiscal 2025 it was 100.0%, against 100.0% the year before. The highest annual figure on record is 180.5% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100.0% | +0.0 |
| FY2024 | Dec 31, 2024 | 100.0% | +0.0 |
| FY2023 | Dec 31, 2023 | 100.0% | +1.7 |
| FY2022 | Dec 31, 2022 | 98.3% | −1.2 |
| FY2021 | Dec 31, 2021 | 99.5% | −81.0 |
| FY2020 | Dec 31, 2020 | 180.5% | +119.6 |
| FY2019 | Dec 31, 2019 | 60.9% | −9.3 |
| FY2018 | Dec 31, 2018 | 70.1% | −23.1 |
| FY2017 | Dec 31, 2017 | 93.3% | +27.3 |
| FY2016 | Dec 31, 2016 | 66.0% | −1.4 |
| FY2015 | Dec 31, 2015 | 67.4% | +15.6 |
| FY2014 | Dec 31, 2014 | 51.8% | −45.0 |
| FY2013 | Dec 31, 2013 | 96.7% | −1.5 |
| FY2012 | Dec 31, 2012 | 98.3% | −0.8 |
| FY2011 | Dec 31, 2011 | 99.1% | +7.6 |
| FY2010 | Dec 31, 2010 | 91.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 100.0% | +0.0 |
| Q1 FY2026 | Mar 31, 2026 | 100.0% | +0.0 |
| Q4 FY2025 | Dec 31, 2025 | 100.0% | +0.0 |
| Q3 FY2025 | Sep 30, 2025 | 100.0% | +0.0 |
| Q2 FY2025 | Jun 30, 2025 | 100.0% | +0.0 |
| Q1 FY2025 | Mar 31, 2025 | 100.0% | +0.0 |
| Q4 FY2024 | Dec 31, 2024 | 100.0% | +0.0 |
| Q3 FY2024 | Sep 30, 2024 | 100.0% | +0.0 |
| Q2 FY2024 | Jun 30, 2024 | 100.0% | +0.0 |
| Q1 FY2024 | Mar 31, 2024 | 100.0% | +0.0 |
| Q4 FY2023 | Dec 31, 2023 | 100.0% | +0.0 |
| Q3 FY2023 | Sep 30, 2023 | 100.0% | +35.4 |
| Q2 FY2023 | Jun 30, 2023 | 100.0% | +0.0 |
| Q1 FY2023 | Mar 31, 2023 | 100.0% | +0.0 |
| Q4 FY2022 | Dec 31, 2022 | 100.0% | +0.0 |
| Q3 FY2022 | Sep 30, 2022 | 64.6% | −8.0 |
| Q4 FY2021 | Dec 31, 2021 | 100.0% | −1.3 |
| Q3 FY2021 | Sep 30, 2021 | 100.0% | −62.9 |
| Q2 FY2021 | Jun 30, 2021 | 100.0% | −1233.0 |
| Q1 FY2021 | Mar 31, 2021 | 72.6% | −27.4 |
| Q4 FY2020 | Dec 31, 2020 | 101.3% | +97.2 |
| Q3 FY2020 | Sep 30, 2020 | 162.9% | +65.2 |
| Q2 FY2020 | Jun 30, 2020 | 1333.0% | +1284.3 |
| Q1 FY2020 | Mar 31, 2020 | 100.0% | +4.5 |
| Q4 FY2019 | Dec 31, 2019 | 4.0% | −94.2 |
| Q3 FY2019 | Sep 30, 2019 | 97.8% | +16.8 |
| Q2 FY2019 | Jun 30, 2019 | 48.7% | −10.7 |
| Q1 FY2019 | Mar 31, 2019 | 95.5% | +45.9 |
| Q4 FY2018 | Dec 31, 2018 | 98.2% | −3.0 |
| Q3 FY2018 | Sep 30, 2018 | 81.0% | −10.9 |
| Q2 FY2018 | Jun 30, 2018 | 59.4% | +59.8 |
| Q1 FY2018 | Mar 31, 2018 | 49.6% | −37.9 |
| Q4 FY2017 | Dec 31, 2017 | 101.2% | −36.0 |
| Q3 FY2017 | Sep 30, 2017 | 91.9% | +185.7 |
| Q2 FY2017 | Jun 30, 2017 | -0.4% | −75.8 |
| Q1 FY2017 | Mar 31, 2017 | 87.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 137.2% | – |
| Q3 FY2016 | Sep 30, 2016 | -93.9% | – |
| Q2 FY2016 | Jun 30, 2016 | 75.4% | – |
See a number that looks wrong?